Clinical impact of mucinous and poorly differentiated tumours on the outcome of patients with stage II colon cancer: A TOSCA subgroup analysis
G. Rosati, Giacomo Bregni(Institut Jules Bordet), Fabrizio Artioli(Roche (Switzerland)), Monica Ronzoni, Francesca Galli(University of Modena and Reggio Emilia), Rodolfo Mattioli(Ospedali Riuniti Marche Nord), Paolo Marchetti(Istituto Dermopatico dell'Immacolata), Maurizio Cantore, Sara Lonardi(Istituto Oncologico Veneto), Domenico Corsi(Ospedale San Carlo), Anna Maria Bochicchio(Ospedale San Carlo), Maria Di Bartolomeo(Fondazione IRCCS Istituto Nazionale dei Tumori), Silvia Bozzarelli(IRCCS Humanitas Research Hospital), Nicoletta Pella(University of Udine), Maria Giulia Zampino(Azienda Ospedaliera Universitaria Pisana), Roberto Labianca(Ospedale Papa Giovanni XXIII), Fabio Galli(Mario Negri Institute for Pharmacological Research), Maria Banzi(Azienda Ospedaliera S.Maria), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), Stefano Tamberi(Azienda Unità Sanitaria Locale Della Romagna)
Cited by 0
Related Papers
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k